ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
批准号：
472342
负责人：
Boudreault Pierre-Luc
金额：
$7.29万
依托单位：
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2023-09-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our interdisciplinary research team has developed and patented a new antibiotic class from a natural product, Tomatidine (TO). These novel molecules are potent broad-spectrum antibiotics. TM-184, our first lead candidate, demonstrated good activity agains
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
